Table of Contents
This report prepared by La Merie Publishing provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2015. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 9, 2016. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mosty are presented as reported (not based on constant exchange rates).
A total of 39 biologic therapeutics reached blockbuster status with 2015 sales exceeding US$ 1 bln: 21 antibodies and 18 proteins. Nine biologics reached global sales in 2015 of more than US$ 5 bln. Four biologics were new in the blockbuster biologics list and one dropped out. Six biopharmaceutical companies posted combined biologics sales of more than US$ 10 bln in the year 2015.
Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2015 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2015 and the percentage of antibody sales of total biologics sales.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Use this report to: - Identify key market dynamics and the factors impacting the global protein-labeling market and its subsegments. - Gain insight into global protein-labeling market and its market segments, ...
“The protein hydrolysates market is projected to grow at a significant rate” The protein hydrolysates market is projected to grow at a CAGR of 8.1% from 2016, to reach USD 738.2 million by 2022. The ...
“Protein Ingredients Market projected to grow at a CAGR of 6.0%” The protein ingredients market has grown rapidly in the last few years and is projected to reach USD 58.49 billion by 2022 at a CAGR ...